These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 12623056)

  • 1. Evaluation of a botulinum fragment C-based ELISA for measuring the humoral immune response in primates.
    Lindsey CY; Smith LA; West MW; Boles JW; Brown JE
    Biologicals; 2003 Mar; 31(1):17-24. PubMed ID: 12623056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey.
    Boles J; West M; Montgomery V; Tammariello R; Pitt ML; Gibbs P; Smith L; LeClaire RD
    Toxicon; 2006 Jun; 47(8):877-84. PubMed ID: 16730042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
    Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
    Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High sensitivity ELISA for detection of botulinum neurotoxin serotype F.
    Liu Z; Zhang C; Li Y; Song C; Sun Y; Wei Y; Xu Z; Yang A; Xu Z; Yang K; Jin B
    Hybridoma (Larchmt); 2012 Aug; 31(4):233-9. PubMed ID: 22894775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D.
    Stahl C; Unger L; Mazuet C; Popoff M; Straub R; Frey J
    Vaccine; 2009 Sep; 27(41):5661-6. PubMed ID: 19646409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
    Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW
    Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay.
    Siegel LS
    J Clin Microbiol; 1988 Nov; 26(11):2351-6. PubMed ID: 3235662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.
    Gao YL; Gao S; Kang L; Nie C; Wang JL
    Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative vaccination against equine botulism (BoNT/C).
    Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R
    Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice.
    Woodward LA; Arimitsu H; Hirst R; Oguma K
    Infect Immun; 2003 May; 71(5):2941-4. PubMed ID: 12704175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of recombinant vaccines for botulinum neurotoxin.
    Smith LA
    Toxicon; 1998 Nov; 36(11):1539-48. PubMed ID: 9792170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relation between toxicity and toxin-related-antigen contents of Clostridium botulinum types C and D cultures as determined by mouse bioassay and ELISA.
    Notermans S; Dufrenne J; Kozaki S
    Jpn J Med Sci Biol; 1982; 35(5-6):203-11. PubMed ID: 6761472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New equine antitoxins to botulinum neurotoxins serotypes A and B.
    Li D; Mattoo P; Keller JE
    Biologicals; 2012 Jul; 40(4):240-6. PubMed ID: 22560800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of biophysical characterization in preformulation development of a heavy-chain fragment of botulinum serotype B: evaluation of suitable purification process conditions.
    Bedu-Addo FK; Johnson C; Jeyarajah S; Henderson I; Advant SJ
    Pharm Res; 2004 Aug; 21(8):1353-61. PubMed ID: 15359569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunogenicity in humans of a botulinum type F vaccine.
    Montgomery VA; Makuch RS; Brown JE; Hack DC
    Vaccine; 1999 Nov; 18(7-8):728-35. PubMed ID: 10547433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SiMa Cells for a Serotype Specific and Sensitive Cell-Based Neutralization Test for Botulinum Toxin A and E.
    Bak N; Rajagopal S; Stickings P; Sesardic D
    Toxins (Basel); 2017 Jul; 9(7):. PubMed ID: 28726719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of Clostridium botulinum type B toxin in the presence of a lethal substance interfering with toxin neutralization.
    Dezfulian M; Bartlett JG
    Diagn Microbiol Infect Dis; 1985 Mar; 3(2):105-12. PubMed ID: 3884243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris.
    Potter KJ; Bevins MA; Vassilieva EV; Chiruvolu VR; Smith T; Smith LA; Meagher MM
    Protein Expr Purif; 1998 Aug; 13(3):357-65. PubMed ID: 9693060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a monoclonal antibody-based immunoassay for detecting type B Clostridium botulinum toxin produced in pure culture and an inoculated model cured meat system.
    Gibson AM; Modi NK; Roberts TA; Hambleton P; Melling J
    J Appl Bacteriol; 1988 Apr; 64(4):285-91. PubMed ID: 3049499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris.
    Byrne MP; Titball RW; Holley J; Smith LA
    Protein Expr Purif; 2000 Apr; 18(3):327-37. PubMed ID: 10733887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.